# ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

> **NCT04523129** · PHASE3 · COMPLETED · sponsor: **Novaliq GmbH** · enrollment: 834 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** CyclASol topical ocular, eye drops
- **DRUG:** Vehicle topical ocular, eye drops

## Key facts

- **NCT ID:** NCT04523129
- **Lead sponsor:** Novaliq GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-05
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-10-08
- **Target enrollment:** 834 (ACTUAL)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523129, "ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04523129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*